DiabetesTreatment

Eli Lilly's Mounjaro Misses Out on Dedicated Sleep Apnea Approval in Europe

10 days ago

In a significant development for the pharmaceutical industry, Eli Lilly's diabetes drug, Mounjaro, has been denied a separate label for the treatment of sleep apnea in Europe. This decision, announced recently, highlights the ongoing complexities within the regulatory landscape governing medical treatments and their approvals across different markets.

Sandoz Strategizes Quick Launch of Generic Ozempic in Canada

12 days ago

Sandoz, a subsidiary of Novartis, has unveiled its plans to swiftly introduce a generic version of the diabetes medication Ozempic in Canada. This move comes amid rising demand for affordable diabetes treatment options in the country, where the cost of medications has been a significant concern for many patients and healthcare providers alike.

Novo Nordisk's Ozempic Production Facility Under Fire for Quality Control Issues by FDA

2 months ago

In a significant regulatory development, Novo Nordisk's manufacturing plant responsible for producing the widely used diabetes medication, Ozempic, has come under scrutiny from the U.S. Food and Drug Administration (FDA). The FDA cited the facility for multiple quality lapses, raising concerns about the safety and efficacy of the product that has gained immense popularity in recent years.

Revolutionary Findings: Novo's Ozempic Shows Promise in Reducing Alzheimer's Diagnoses

2 months ago

In a groundbreaking development, recent research has suggested that Novo Nordisk’s diabetes medication, Ozempic, may significantly reduce the incidence of Alzheimer's disease among patients using the drug. This insight has stirred excitement in both the medical community and pharmaceutical industry as the prevalence of Alzheimer's continues to rise globally, posing a substantial challenge to public health systems.

Pharmaceutical Game Changer: Mounjaro and Zepbound Supply Shortage Resolved

3 months ago

In a welcome breakthrough for both pharmaceutical companies and patients dependent on vital obesity and diabetes medicines, supply shortages of Mounjaro and Zepbound have finally been resolved. These medicines, which play a vital role in the management of diabetes and weight loss, were under short supply resulting from unforeseen demand and complex interruptions in supply. Recently, there has been promising news in the announcements of drug manufacturers as early signals of stabilization in the availability of these vital drugs have shown signs.